Pharmacokinetics and pharmacodynamics of the GCN2 activator HC-7366 in a phase 1a study in patients with advanced solid tumors.
Journal of Clinical Oncology · 2026-05-28
Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid.
Journal of Clinical Oncology · 2026-05-28
Abstract 1183: Early ctDNA quantification by ctFE outperforms Max VAF for survival stratification across locally advanced and oligometastatic NSCLC treated with radiotherapy.
Cancer Research · 2026-04-03
Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2026-04-01 · 5 citations
1O Efficacy and safety of setidegrasib in patients (pts) with advanced NSCLC with KRAS G12D mutation
ESMO Open · 2026-03-17
142TiP A phase I/II study of EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in advanced RET fusion-positive NSCLC
ESMO Open · 2026-03-17
Abstract LB-A003: Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial
Cancer Immunology Research · 2026-03-05
An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression
Endocrine Abstracts · 2026-03-04
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with genitourinary extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
Journal of Clinical Oncology · 2026-03-01
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
Journal of Thoracic Oncology · 2026-02-01 · 2 citations
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond
Journal of Clinical Oncology · 2026-01-22
1068 Risk of ICU admission after immune checkpoint inhibitor use: real-world data analysis at a national level
Regular and Young Investigator Award Abstracts · 2025-11-01
648 A pilot study to evaluate the combination of zimberelimab, domvanalimab and etrumadenant in patients with previously treated non-small cell lung cancer (NSCLC)
Regular and Young Investigator Award Abstracts · 2025-11-01
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer
Journal of Clinical Oncology · 2025-10-19 · 5 citations
P3.18.88 Title:TUB-030, a Novel Adc: A Phase I/IIA Multi-Center, FIH Trial (5-STAR 1-01) in Patients With Advanced/Metastatic Solid Tumors
Journal of Thoracic Oncology · 2025-10-01
P1.11.78 NAI, An IL-15 Superagonist, A New Class Of Lymphocyte Stimulating Agent (LSA) Prolongs OS In NSCLC By Reversing Lymphopenia
Journal of Thoracic Oncology · 2025-10-01
P2.08.51 Outcomes From a Phase II Study of Hypofractionated Chemoradiation and Consolidation Immunotherapy in Locally-Advanced NSCLC
Journal of Thoracic Oncology · 2025-10-01
OA06.04 Safety and Efficacy of ABBV-706, a Seizure-related Homolog Protein 6-targeting Antibody-drug Conjugate, in R/R SCLC
Journal of Thoracic Oncology · 2025-10-01 · 4 citations
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Journal of the National Comprehensive Cancer Network · 2025-09-01 · 47 citations
2777P Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer
Annals of Oncology · 2025-09-01